Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric Cancer

Samsung Medical Center66 enrolled

Overview

1. Metastatic gastric cancer patients who failed standard treatment will be enrolled in this study. 2. After consent form, patient-derived cancer cell will be collected and tested with 3 kinds of drugs (sunitinib, gefitinib, imatinib). 3. Drug sensitivity prediction software (IRCR-DReSS) will present level of sensitivity and patients will be treated with sensitive drugs. 4. Patients will be evaluated every 6 weeks.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Stomach Neoplasms

Interventions

SunitinibDRUG

sunitinib 37.5mg daily

GefitinibDRUG

Gefitinib 250mg daily

ImatinibDRUG

Imatinib 400mg daily

Eligibility

Sex: ALLMin age: 20 Years

Medical Language ↔ Plain English

Inclusion Criteria: * age\>-20 * metastatic gastric cancer * life expectancy \>-3 months * ascites and pleural effusion that can be drained * ECOG 0-2 * Proper organ function * Patients who will be enrolled in sunitinib, gefitinib, imatinib clinical trial Exclusion Criteria: * HBeAg, HCV, HIV (+) * Active infection * Uncontrolled systemic disease

Locations (1)

Samsung Medical Center

Seoul, South Korea

Outcomes

Primary Outcomes

response rate

Time frame: 2 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.